AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31358717 — intervention group
Group type: EXPERIMENTAL
Intervention: Amorphous Calcium Phosphate (ACP) containing adhesive
Number of subjects: 23
Study 31358717 — intervention group
Group type: COMPARATOR
Intervention: Regular adhesive (control)
Number of subjects: 23
Study 28387616 — intervention group
Group type: EXPERIMENTAL
Intervention: Prestige LP artificial disc replacement (ADR)
Number of subjects: 397
Study 28387616 — intervention group
Group type: COMPARATOR
Intervention: ACDF (anterior cervical discectomy and fusion)
Number of subjects: 397
Study 25516196 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide 10 mg 3× daily via nasogastric tube for 21 days
Number of subjects: 60
Study 25516196 — intervention group
Group type: COMPARATOR
Intervention: Placebo 3× daily via nasogastric tube for 21 days
Number of subjects: 60
Study 25516196 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide
Number of subjects: 60
Study 25516196 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 22951068 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadone maintenance treatment (mean dose 95.7mg, SD 48.9)
Number of subjects: 489
Study 22951068 — intervention group
Group type: EXPERIMENTAL
Intervention: Prescribed opioids (38.8%)
Number of subjects: 489
Study 22951068 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-opioids (48.9%)
Number of subjects: 489
Study 22951068 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-management approaches (60.8%) including prayer (33.8%), vitamins (29.5%), distraction (12.7%)
Number of subjects: 489
Study 22951068 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher methadone dose
Number of subjects: 489
Study 22951068 — intervention group
Group type: EXPERIMENTAL
Intervention: More medical comorbidities
Number of subjects: 489
Study 22951068 — intervention group
Group type: EXPERIMENTAL
Intervention: More severe depressive symptomatology
Number of subjects: 489
Study 22951068 — intervention group
Group type: EXPERIMENTAL
Intervention: Urine drug screening (UDS) positive for opiates, cocaine, and amphetamines
Number of subjects: 489
Study 22951068 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported substance use
Number of subjects: 489
Study 21436459 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP) dropped from optimum to suboptimum pressures for 3-5 minutes during sleep
Number of subjects: 14
Study 21436459 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiological model of OSA
Number of subjects: 14
Study 21436459 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeatability measurements
Number of subjects: 14
Study 19697301 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo
Number of subjects: 60
Study 19697301 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (administered in one double-blind group)
Number of subjects: 60
Study 19697301 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 60
Study 19697301 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo (double-blind)
Number of subjects: 60
Study 17898344 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram treatment for up to 14 weeks
Number of subjects: 1915
Study 14698135 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel (weekly or every 3 weeks)
Number of subjects: 90
Study 14698135 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel (weekly)
Number of subjects: 90
Study 14698135 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel (every 3 weeks)
Number of subjects: 90
Study 14698135 — intervention group
Group type: COMPARATOR
Intervention: FAC chemotherapy
Number of subjects: 90
Study 14698135 — intervention group
Group type: COMPARATOR
Intervention: Healthy volunteers (control)
Number of subjects: 90
Study 12405649 — intervention group
Group type: EXPERIMENTAL
Intervention: Prebiotic mixture (6 g/d of a 70% raftilose and 30% raftiline mixture)
Number of subjects: 43
Study 12405649 — intervention group
Group type: COMPARATOR
Intervention: Placebo (6 g of maltodextrin powder)
Number of subjects: 43
Study 9680679 — intervention group
Group type: EXPERIMENTAL
Intervention: Low inhibitory control conditions (e.g., misleading pictorial cues or arrows)
Number of subjects: 3
Study 9680679 — intervention group
Group type: EXPERIMENTAL
Intervention: High inhibitory control conditions (deceptive pointing)
Number of subjects: 3
Study 9680679 — intervention group
Group type: COMPARATOR
Intervention: Anonymous and public conditions using an arrow to deceive
Number of subjects: 3
Study 9680679 — intervention group
Group type: EXPERIMENTAL
Intervention: Well-controlled conditions for deceptive and nondeceptive tasks
Number of subjects: 3
Study 8021037 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4% SnF2 gel (n = 30) used twice daily for 18 months
Number of subjects: 95
Study 8021037 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05% NaF rinse (n = 30) used with 1100 ppm F toothpaste
Number of subjects: 95
Study 8021037 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 35) using only standard fluoride (1100 ppm F) toothpaste
Number of subjects: 95
Study 2681637 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant somatropin, 0.1 mg/kg three times a week
Number of subjects: 121
Study 2681637 — intervention group
Group type: COMPARATOR
Intervention: Untreated (control group)
Number of subjects: 121
Study 30270047 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral acetaminophen administered within 1 hour of induction
Number of subjects: 37
Study 30270047 — intervention group
Group type: COMPARATOR
Intervention: Fasting (control group)
Number of subjects: 37
Study 30270047 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral acetaminophen (treatment group)
Number of subjects: 37
Study 29066159 — intervention group
Group type: EXPERIMENTAL
Intervention: n‐3 long‐chain polyunsaturated fatty acids (LCPUFA) 4 g/d for three months
Number of subjects: 422
Study 29066159 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 422
Study 29066159 — intervention group
Group type: EXPERIMENTAL
Intervention: n‐3 LCPUFA
Number of subjects: 422
Study 26287149 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboxymethyl-glucan (CM-G) administered orally for 60 days
Number of subjects: 0
Study 26287149 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 23003110 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipolar plasmakinetic energy transurethral resection of the bladder
Number of subjects: 132
Study 23003110 — intervention group
Group type: COMPARATOR
Intervention: Conventional monopolar transurethral resection of the bladder
Number of subjects: 132
Study 21429334 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific immunotherapy (n = 32)
Number of subjects: 64
Study 21429334 — intervention group
Group type: COMPARATOR
Intervention: Medical treatment (n = 32)
Number of subjects: 64
Study 18657806 — intervention group
Group type: COMPARATOR
Intervention: Endoscopic SEMS
Number of subjects: 85
Study 18657806 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous SEMS
Number of subjects: 85
Study 18657806 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (successful biliary drainage)
Number of subjects: 85
Study 18657806 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (after successful biliary decompression)
Number of subjects: 85
Study 17407369 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine (50 or 100 mg doses)
Number of subjects: 0
Study 17407369 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 15065981 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential lineup with absolute height encoding
Number of subjects: 0
Study 15065981 — intervention group
Group type: COMPARATOR
Intervention: Simultaneous lineup with relative height encoding
Number of subjects: 0
Study 11731354 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine 10 mg daily for 1 week, then increased to 20 mg daily
Number of subjects: 0
Study 11731354 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9272346 — intervention group
Group type: EXPERIMENTAL
Intervention: Acellular vaccines
Number of subjects: 0
Study 9272346 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-cell vaccine
Number of subjects: 0
Study 9272346 — intervention group
Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 0
Study 7840402 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine anaesthesia (n = 20)
Number of subjects: 54
Study 7840402 — intervention group
Group type: EXPERIMENTAL
Intervention: General intubation anaesthesia (n = 18)
Number of subjects: 54
Study 7840402 — intervention group
Group type: COMPARATOR
Intervention: No anaesthesia (Control group, n = 16)
Number of subjects: 54
Study 2736427 — intervention group
Group type: EXPERIMENTAL
Intervention: Base product plus sunset yellow/tartrazine
Number of subjects: 19
Study 2736427 — intervention group
Group type: EXPERIMENTAL
Intervention: Base product plus sodium metabisulphite/sodium benzoate
Number of subjects: 19
Study 2736427 — intervention group
Group type: COMPARATOR
Intervention: Base product alone (placebo)
Number of subjects: 19
Study 2736427 — intervention group
Group type: EXPERIMENTAL
Intervention: Base product alone, base product plus sunset yellow/tartrazine, base product plus sodium metabisulphite/sodium benzoate
Number of subjects: 19
Study 1093429 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive end-expiratory pressure (PEEP)
Number of subjects: 7
Study 1093429 — intervention group
Group type: COMPARATOR
Intervention: Control (without PEEP)
Number of subjects: 7
Study 31252090 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness Meditation (MM)
Number of subjects: 69
Study 31252090 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Cognitive Therapy (MBCT)
Number of subjects: 69
Study 31252090 — intervention group
Group type: COMPARATOR
Intervention: Cognitive Therapy (CT)
Number of subjects: 69
Study 29958013 — intervention group
Group type: EXPERIMENTAL
Intervention: Fear appeal messages with high threat and efficacy
Number of subjects: 0
Study 29958013 — intervention group
Group type: EXPERIMENTAL
Intervention: Fear arousal
Number of subjects: 0
Study 29958013 — intervention group
Group type: EXPERIMENTAL
Intervention: Blunting coping style
Number of subjects: 0
Study 29958013 — intervention group
Group type: EXPERIMENTAL
Intervention: Monitoring coping style
Number of subjects: 0
Study 28315481 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient Advocate (PA) intervention
Number of subjects: 312
Study 28315481 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 312
Study 25398562 — intervention group
Group type: EXPERIMENTAL
Intervention: Very low nicotine content (VLNC) cigarettes provided for 12 weeks
Number of subjects: 33
Study 25398562 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual cigarette brand)
Number of subjects: 33
Study 24622005 — intervention group
Group type: EXPERIMENTAL
Intervention: ASCEND-HF trial patients (Nesiritide treatment)
Number of subjects: 3149
Study 24622005 — intervention group
Group type: COMPARATOR
Intervention: Population-level cohorts (not specified treatment)
Number of subjects: 3149
Study 16526312 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral bicarbonate therapy (1.2 mEq/kg of body weight daily)
Number of subjects: 40
Study 16526312 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 12707480 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive-expressive group intervention (GI)
Number of subjects: 85
Study 12707480 — intervention group
Group type: COMPARATOR
Intervention: Educational control condition (EC)
Number of subjects: 85
Study 10628543 — intervention group
Group type: EXPERIMENTAL
Intervention: Tonsillotomy (TT) with CO2-laser
Number of subjects: 41
Study 10628543 — intervention group
Group type: COMPARATOR
Intervention: Tonsillectomy (TE)
Number of subjects: 41
Study 7853949 — intervention group
Group type: EXPERIMENTAL
Intervention: Social services case-management
Number of subjects: 80
Study 7853949 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 80
Study 1750016 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal sprays of recombinant alpha 2 interferon (3 x 10(6) IU) twice daily for five days
Number of subjects: 123
Study 1750016 — intervention group
Group type: COMPARATOR
Intervention: Placebo twice daily for five days
Number of subjects: 123
Study 6285281 — intervention group
Group type: EXPERIMENTAL
Intervention: Isaxonine
Number of subjects: 0
Study 6285281 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30820429 — intervention group
Group type: EXPERIMENTAL
Intervention: Incise drape (ID) used in treatment group
Number of subjects: 88
Study 29099872 — intervention group
Group type: EXPERIMENTAL
Intervention: EKG heart rate displayed to clinical team
Number of subjects: 40
Study 29099872 — intervention group
Group type: COMPARATOR
Intervention: EKG heart rate not displayed to clinical team
Number of subjects: 40
Study 25429384 — intervention group
Group type: EXPERIMENTAL
Intervention: High maternal milk feeds (MMFs) at second week
Number of subjects: 97
Study 25429384 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal age
Number of subjects: 97
Study 25429384 — intervention group
Group type: EXPERIMENTAL
Intervention: Assisted reproduction technology
Number of subjects: 97
Study 25429384 — intervention group
Group type: EXPERIMENTAL
Intervention: Employment
Number of subjects: 97
Study 25429384 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonuniversity education
Number of subjects: 97
Study 25429384 — intervention group
Group type: EXPERIMENTAL
Intervention: Non‐Nordic origin
Number of subjects: 97
Study 25429384 — intervention group
Group type: EXPERIMENTAL
Intervention: Overweight
Number of subjects: 97
Study 23311304 — intervention group
Group type: EXPERIMENTAL
Intervention: Cogmed computerized working memory training
Number of subjects: 100
Study 23311304 — intervention group
Group type: EXPERIMENTAL
Intervention: Paying attention in class intervention (experimental school-based executive function training)
Number of subjects: 100
Study 20848500 — intervention group
Group type: EXPERIMENTAL
Intervention: Open-label adalimumab weekly therapy
Number of subjects: 260
Study 20848500 — intervention group
Group type: EXPERIMENTAL
Intervention: Open-label adalimumab EOW therapy
Number of subjects: 260
Study 20848500 — intervention group
Group type: COMPARATOR
Intervention: Blinded adalimumab EOW therapy
Number of subjects: 260
Study 18435189 — intervention group
Group type: EXPERIMENTAL
Intervention: AdheSe (ADH) with additional phosphoric acid etching
Number of subjects: 70
Study 18435189 — intervention group
Group type: EXPERIMENTAL
Intervention: Xeno III (XE) with additional phosphoric acid etching
Number of subjects: 70
Study 18435189 — intervention group
Group type: EXPERIMENTAL
Intervention: Futurabond NR (FNR) with additional phosphoric acid etching
Number of subjects: 70
Study 18435189 — intervention group
Group type: COMPARATOR
Intervention: Futurabond NR (FNR) without additional phosphoric acid etching
Number of subjects: 70
Study 16877490 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium salts (CaS)
Number of subjects: 64
Study 16877490 — intervention group
Group type: COMPARATOR
Intervention: Sevelamer
Number of subjects: 64
Study 12806613 — intervention group
Group type: EXPERIMENTAL
Intervention: Branched-chain amino acids (BCAA)
Number of subjects: 174
Study 11034934 — intervention group
Group type: EXPERIMENTAL
Intervention: VLDL-apoB
Number of subjects: 4159
Study 11034934 — intervention group
Group type: EXPERIMENTAL
Intervention: apoCIII in VLDL+LDL
Number of subjects: 4159
Study 11034934 — intervention group
Group type: EXPERIMENTAL
Intervention: apoE in HDL
Number of subjects: 4159
Study 11034934 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma triglycerides
Number of subjects: 4159
Study 8660045 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (70 mg/kg given over 7 d)
Number of subjects: 326
Study 8660045 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofloxacin (45‐50 mg/kg given over 3‐5 d)
Number of subjects: 326
Study 8660045 — intervention group
Group type: COMPARATOR
Intervention: Control group (children who had not contracted typhoid or received any fluoroquinolones)
Number of subjects: 326
Study 8660045 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin and Ofloxacin
Number of subjects: 326
Study 1891222 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumatic retinopexy (PR)
Number of subjects: 179
Study 1891222 — intervention group
Group type: COMPARATOR
Intervention: Scleral buckling (SB)
Number of subjects: 179
Study 6872416 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual lorazepam 2 mg every 2 hr with supportive care (21 patients)
Number of subjects: 41
Study 6872416 — intervention group
Group type: COMPARATOR
Intervention: Sublingual placebo every 2 hr with supportive care (20 patients)
Number of subjects: 41
Study 6872416 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (21 drug group and 20 no-drug group)
Number of subjects: 41
Study 31938818 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 (3490 ± 1465 IU/day)
Number of subjects: 260
Study 31938818 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 260
Study 31938818 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 and Placebo
Number of subjects: 260
Study 30703096 — intervention group
Group type: EXPERIMENTAL
Intervention: Mass deworming treatment
Number of subjects: 0
Study 30270688 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 (2100 IE q.d. for 48 weeks)
Number of subjects: 0
Study 30270688 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 26932178 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus
Number of subjects: 300
Study 26932178 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporine
Number of subjects: 300
Study 24755106 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem-solving therapy (PST) for 6 weeks from a licensed renal social worker
Number of subjects: 38
Study 24755106 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 38
Study 22318468 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) 1,200 mg daily for 6 weeks
Number of subjects: 11
Study 22318468 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) 2,400 mg daily for 6 weeks
Number of subjects: 11
Study 19155337 — intervention group
Group type: EXPERIMENTAL
Intervention: Morning shift workers (Group I)
Number of subjects: 70
Study 19155337 — intervention group
Group type: COMPARATOR
Intervention: Afternoon shift workers (Group II)
Number of subjects: 70
Study 19155337 — intervention group
Group type: EXPERIMENTAL
Intervention: Individuals working 12 hours (Group III)
Number of subjects: 70
Study 17448578 — intervention group
Group type: EXPERIMENTAL
Intervention: Killed oral vaccine for enterotoxigenic E. coli (ETEC) diarrhoea, two doses with colonization factor antigens (CF) and cholera B subunit
Number of subjects: 672
Study 17448578 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 672
Study 15900094 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemocoagulase in addition to mechanical ventilation
Number of subjects: 48
Study 15900094 — intervention group
Group type: COMPARATOR
Intervention: Mechanical ventilation only
Number of subjects: 48
Study 12421104 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicalutamide 150 mg/day as an adjunct to radiotherapy, radical prostatectomy or watchful waiting
Number of subjects: 0
Study 12421104 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicalutamide 150 mg/day monotherapy
Number of subjects: 0
Study 12421104 — intervention group
Group type: COMPARATOR
Intervention: Castration (medical or surgical)
Number of subjects: 0
Study 12421104 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicalutamide 150 mg/day
Number of subjects: 0
Study 9708750 — intervention group
Group type: EXPERIMENTAL
Intervention: Levonorgestrel (0.75 mg, repeated 12 h later)
Number of subjects: 1998
Study 9708750 — intervention group
Group type: COMPARATOR
Intervention: Yuzpe regimen (ethinyloestradiol 100 microg plus levonorgestrel 0.5 mg, repeated 12 h later)
Number of subjects: 1998
Study 8567563 — intervention group
Group type: EXPERIMENTAL
Intervention: Graded epinephrine infusion (0.02-0.12 micrograms.kg-1.min-1)
Number of subjects: 8
Study 8567563 — intervention group
Group type: COMPARATOR
Intervention: Control test (no epinephrine infusion)
Number of subjects: 8
Study 2213379 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-blind, placebo-controlled food challenge (DBPCFC)
Number of subjects: 480
Study 2213379 — intervention group
Group type: EXPERIMENTAL
Intervention: Open challenges with large amounts of challenge food
Number of subjects: 480
Study 352100 — intervention group
Group type: EXPERIMENTAL
Intervention: Streptokinase
Number of subjects: 20
Study 352100 — intervention group
Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 20
Study 27364093 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy nuts
Number of subjects: 17
Study 27364093 — intervention group
Group type: COMPARATOR
Intervention: Control food
Number of subjects: 17
Study 27364093 — intervention group
Group type: EXPERIMENTAL
Intervention: Equol + ODMA producers
Number of subjects: 17
Study 27364093 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonproducers
Number of subjects: 17
Study 25769742 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (DEX)
Number of subjects: 0
Study 25769742 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 23865591 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyoscine butylbromide (HBB) 20-100 mg/day
Number of subjects: 175
Study 23865591 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 175
Study 21843017 — intervention group
Group type: EXPERIMENTAL
Intervention: Fatigued individuals working alone
Number of subjects: 171
Study 21843017 — intervention group
Group type: EXPERIMENTAL
Intervention: Fatigued individuals working in teams
Number of subjects: 171
Study 21843017 — intervention group
Group type: EXPERIMENTAL
Intervention: Teams with a relatively less fatigued member
Number of subjects: 171
Study 21843017 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants cued toward more direct strategies
Number of subjects: 171
Study 19793466 — intervention group
Group type: EXPERIMENTAL
Intervention: Humidified-warm gas
Number of subjects: 113
Study 19793466 — intervention group
Group type: COMPARATOR
Intervention: Dry-heated gas
Number of subjects: 113
Study 19793466 — intervention group
Group type: COMPARATOR
Intervention: Traditional dry-cold gas
Number of subjects: 113